GUB-UCN2 is an experimental peptide being studied to answer a question many people have when losing weight: can you lose fat without losing muscle?

Gubra, the company developing it, has reported encouraging results in animals. Testing in people has begun, but we still don't know whether they will get the same benefits. Gubra's trial announcement

What Is GUB-UCN2?

Your body uses chemical signals to help its tissues do their jobs. One of these is urocortin 2, also called UCN2. It is a peptide, a short chain of amino acids. These are small building blocks the body uses to make different substances.

GUB-UCN2 is Gubra's modified version of that signal. It is designed to act longer than natural urocortin 2, with the aim of allowing weekly treatment. Scientists are studying how it acts on muscles and whether it could change the amount of fat and muscle in the body.

Is It a GLP-1?

No. It acts on a receiving point on cells, called a receptor, that differs from the one used by GLP-1 medicines such as semaglutide.

The trial tests Gubra's compound both alone and alongside weight-loss medicines. That doesn't mean adding it to another treatment has already been shown to work. Trial overview

Could GUB-UCN2 Help You Lose Fat and Keep Muscle?

Gubra reports that its experimental peptide reduced fat and increased muscle in animal studies. When tested alongside a GLP-1 medicine, it also prevented the loss of lean mass seen when that medicine was used alone. These results come from the company's research before testing in people. Gubra's research summary

Lean mass isn't just muscle. It also includes water, organs and other tissues. An increase on a body scan doesn't automatically mean someone has gained that much muscle or become stronger.

You may come across the phrase “muscle-sparing peptide.” For GUB-UCN2, that describes what scientists hope to achieve, not a benefit proved in people.

For practical ways to care for your muscles today, see Losing Weight While Keeping Muscle.

What Will the Human Trial Tell Us?

The first study will examine side effects, how long the compound stays in the body, and early signs of possible benefits.

Gubra plans to include about 188 people, including healthy volunteers and adults with obesity. Some groups will receive a single dose. Others will receive repeated treatment for up to 16 weeks. Gubra's trial plan

The longer periods should help measure changes in fat and muscle. The study will also assess how people move and how well their muscles work. Does a change on a scan come with more strength or easier movement?

This early stage is called Phase 1/2a. It can help decide whether larger trials are worth doing, but it cannot answer every question about long-term benefits and risks. The official trial record has the details.

When Could We See Results?

Gubra expects the first results in the first half of 2027. These will focus mainly on safety and how the body handles a single dose. They won't yet tell us what might happen to fat and muscle after several months of treatment.

The company's October 2026 schedule places results from the six-week groups between late 2027 and early 2028. Results from the 16-week groups are expected in the first half of 2029. Those dates may change. They are estimates for study results, not promises of approval or a product launch. Gubra's research presentation

What Do We Know About Side Effects?

We don't yet have published results in people that establish the side effects of GUB-UCN2 or how often they happen.

Earlier studies tested urocortin 2 given through a vein, not Gubra's longer-acting compound. In a small study of healthy volunteers, urocortin 2 increased heart rate. Another study, in people with heart failure, found that it lowered blood pressure compared with a placebo, a treatment without the active substance. Healthy-volunteer study Heart-failure study

Those findings give scientists reasons to watch heart rate and blood pressure. They do not show that GUB-UCN2 causes the same effects. The compound, the way it is given and the people being studied differ. Its connection to a natural body signal doesn't automatically make it safe, either.

Is GUB-UCN2 Available Yet?

It is still an experimental treatment, not an approved weight-loss medicine. There is no confirmed date when it might become available by prescription. Gubra's development announcement

You may find urocortin II, another way of writing urocortin 2, advertised online for lab research. It is not the same compound as GUB-UCN2. A similar name doesn't make it the modified treatment being studied.

One lab supplier lists “Urocortin II, human” and states that it is for research only, not for use in people. The word “human” identifies the form of the peptide. It doesn't mean the product is approved for someone to use. Supplier's product description

If you're interested in taking part, check the official trial record and ask the study team about eligibility. Results from human trials, rather than promises about products sold online, will help us understand the potential of GUB-UCN2.